Secukinumab: Phase III data

The 132-week, double-blind, international Phase III TRANSFIGURE trial in 198 patients with moderate to severe plaque psoriasis with significant nail psoriasis showed that 300 mg subcutaneous Cosentyx met the primary endpoint of a greater mean percent reduction in NAPSI score from baseline to week 16 vs. placebo (45.3% vs. 10.8%, p<0.0001). Patients received once-weekly placebo or 150 or 300 mg Cosentyx for the first 5 weeks and then every 4 weeks for 128 weeks. Data were presented at the World Congress of Dermatology in Vancouver. ...